Search results
Results from the WOW.Com Content Network
Dora Nellie Richardson (1919-1998) was an organic chemist who first synthesised Tamoxifen in England in 1962. [1] She was born on 1 June 1919 and died in September 1998 in England. [2] Richardson decided to become a chemist after seeing people working in hospital laboratories while visiting her grandmother in hospital in London.
Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. [13] It is also being studied for other types of cancer. [13] It has been used for Albright syndrome. [14] Tamoxifen is typically taken daily by mouth for five years for breast cancer. [14]
AP Images; Bridgeman Art Library: California Digital Library: California State University, Northridge, Oviatt Library Digital Collections Camera Press: Chicago Daily News (1902–1933), collection of over 55,000 images on glass plate negatives Corbis Images: Depositphotos: Stock Images: 164,000,000+ (June 2020) Yes No Yes English (Default)+ 21 ...
N-Desmethyltamoxifen (developmental code name ICI-55,548) is a major metabolite of tamoxifen, a selective estrogen receptor modulator (SERM). [1] [2] N-Desmethyltamoxifen is further metabolized into endoxifen (4-hydroxy-N-desmethyltamoxifen), which is thought to be the major active form of tamoxifen in the body.
Jordan, V.C. A current view of tamoxifen for the treatment and prevention of breast cancer (Gaddum Memorial Lecture)" British Journal of Pharmacology 110:507-517, 1993. (257 citations as of May 26, 2021). Jordan, V.C. and Morrow, M.M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Reviews 20:253-278, 1999.
Free-Images.com – More than 12 Million Public Domain/CC0 stock images, clip-art, historical photos and more. Excellent Search Results. Commercial use OK. No attribution required. No login required. Good Free Photos – All public domain pictures of mainly landscape but wildlife and plants as well
The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial from the early 2000s designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease.
Endoxifen is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). [3] [4] [5] The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce endoxifen and afimoxifene (4-hydroxytamoxifen). [6]